

Oncology Today with Dr Neil Love: Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following proteins is targeted by the investigational antibody-drug conjugate ifinatamab deruxtecan?**
 - a. HER3
 - b. CEACAM5
 - c. MET
 - d. B7-H3**
- 2. Which of the following best describes outcomes from the Phase III CARMEN-LC03 trial evaluating tusamitamab ravtansine for patients with previously treated metastatic nonsquamous NSCLC?**
 - a. Progression-free survival (PFS) was significantly improved
 - b. PFS and overall survival (OS) were significantly improved
 - c. No significant improvement in PFS or OS**
- 3. Patritumab deruxtecan has demonstrated Phase II clinical efficacy in patients with previously treated advanced NSCLC and which of the following genomic alterations?**
 - a. BRAF mutation
 - b. EGFR mutation**
 - c. MET amplification
 - d. ROS1 mutation
- 4. Tumor treating fields promote which of the following antitumor processes?**
 - a. Disruption of mitosis
 - b. Downregulation of DNA damage response
 - c. Interference with cell migration
 - d. Downstream enhancement of antitumor immunity
 - e. All of the above**
- 5. What was the approximate incidence of any-grade stomatitis/oral mucositis reported in patients receiving datopotamab deruxtecan for previously treated advanced NSCLC in the Phase III TROPION-Lung01 study?**
 - a. 14%
 - b. 34%
 - c. 54%**
 - d. 74%